Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
20 Jan, 2022 | 08:57h | UTC
Commentary on Twitter
Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC
Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB
— Paolo Tarantino (@PTarantinoMD) January 18, 2022